Metastatic Malignant Neoplasm in the Liver Clinical Trial
Official title:
Incisional Hernia Prevention After Open Hepatectomy by Small Tissue Bite Fascial Closure: A Randomized Clinical Trial
This clinical trial compares two different kinds of surgical closing techniques, short stitch suture or traditional suture, in patients who are having liver tumor surgery. This study may help researchers learn if one technique can lower the chances of developing a hole in the wall of the abdomen (an abdominal hernia) at the incision site better than the other.
PRIMARY OBJECTIVE: I. To assess whether small bites abdominal wall closure reduces the risk of developing incisional hernia following liver surgery. SECONDARY OBJECTIVES: I. To compare short-term perioperative outcomes between small bites and typical fascial closure technique. II. To assess the hernia incidence rate of short stich versus (vs.) standard closure in subgroups of patients with inverted-L or midline incisions. III. To assess the hernia incidence rate of Kawaguchi-Gayet hepatectomy complexity classifications I/II vs. III (hernia rate by extent of hepatectomy). IV. To assess the hernia incidence rate of preoperative chemotherapy or no preoperative chemotherapy (hernia rate by exposure to preoperative chemotherapy). V. To assess impact of small bites abdominal wall closure on health care quality of life following liver surgery. VI. To assess safety of small tissue bites fascial closure suture technique versus conventional fascial closure following hepatectomy. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I (INTERVENTION): Patients undergo hepatectomy as planned using small bites fascial method for abdominal wall closure. ARM II (CONTROL): Patients undergo hepatectomy as planned using conventional fascial method for abdominal wall closure. After completion of study, patients are followed up at 1-4 weeks, and then at 3, 6, and 12 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03068624 -
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 1 | |
| Recruiting |
NCT04728633 -
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
|
Phase 2 | |
| Recruiting |
NCT05863195 -
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
|
Phase 3 | |
| Active, not recruiting |
NCT02156739 -
Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions
|
N/A | |
| Recruiting |
NCT05039632 -
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05040360 -
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT02738606 -
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
|
Phase 2 | |
| Active, not recruiting |
NCT03472586 -
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
|
Phase 2 | |
| Recruiting |
NCT05791448 -
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
|
Phase 1 | |
| Completed |
NCT00862680 -
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
|
||
| Active, not recruiting |
NCT02070549 -
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
|
Phase 1 | |
| Completed |
NCT02683200 -
MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer
|
Early Phase 1 | |
| Recruiting |
NCT03203525 -
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT03844750 -
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
|
Phase 2 | |
| Active, not recruiting |
NCT02626312 -
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
|
Phase 1 | |
| Active, not recruiting |
NCT02364557 -
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03457948 -
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
|
Phase 2 | |
| Recruiting |
NCT04796818 -
An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
|
N/A | |
| Recruiting |
NCT06016855 -
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
|
Phase 4 |